Cargando…
Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes
BACKGROUND: Gross cystic disease fluid protein 15 (GCDFP-15), which is regulated by the androgen receptor (AR), is a diagnostic marker for mammary differentiation in histopathology. We determined the expression of GCDFP-15 in breast cancer subtypes, its potential prognostic and predictive value, as...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122770/ https://www.ncbi.nlm.nih.gov/pubmed/25070172 http://dx.doi.org/10.1186/1471-2407-14-546 |
_version_ | 1782329388842352640 |
---|---|
author | Darb-Esfahani, Silvia von Minckwitz, Gunter Denkert, Carsten Ataseven, Beyhan Högel, Bernhard Mehta, Keyur Kaltenecker, Gabriele Rüdiger, Thomas Pfitzner, Berit Kittel, Kornelia Fiedler, Bettina Baumann, Klaus Moll, Roland Dietel, Manfred Eidtmann, Holger Thomssen, Christoph Loibl, Sibylle |
author_facet | Darb-Esfahani, Silvia von Minckwitz, Gunter Denkert, Carsten Ataseven, Beyhan Högel, Bernhard Mehta, Keyur Kaltenecker, Gabriele Rüdiger, Thomas Pfitzner, Berit Kittel, Kornelia Fiedler, Bettina Baumann, Klaus Moll, Roland Dietel, Manfred Eidtmann, Holger Thomssen, Christoph Loibl, Sibylle |
author_sort | Darb-Esfahani, Silvia |
collection | PubMed |
description | BACKGROUND: Gross cystic disease fluid protein 15 (GCDFP-15), which is regulated by the androgen receptor (AR), is a diagnostic marker for mammary differentiation in histopathology. We determined the expression of GCDFP-15 in breast cancer subtypes, its potential prognostic and predictive value, as well as its relationship to AR expression. METHODS: 602 pre-therapeutic breast cancer core biopsies from the phase III randomized neoadjuvant GeparTrio trial (NCT00544765) were investigated for GCDFP-15 expression by immunohistochemistry. Expression data were correlated with disease-free (DFS) and overall survival (OS) time as well as pathological complete response (pCR) to neoadjuvant chemotherapy. RESULTS: 239 tumors (39.7%) were GCDFP-15 positive. GCDFP-15 expression was positively linked to hormone receptor (HR) and HER2 positive tumor type, while most triple negative carcinomas were negative (p < 0.0001). GCDFP-15 was also strongly correlated to AR expression (p 0.001), and to the so-called molecular apocrine subtype (HR-/AR+, p < 0.0001). Higher rates of GCDFP-15 positivity were seen in tumors of lower grade (<0.0001) and negative nodal status (p = 0.008). GCDFP-15 positive tumors tended to have a more favourable prognosis than GCDFP-15 negative tumors (DFS (p = 0.052) and OS (p = 0.044)), which was not independent from other factors in multivariate analysis. GCDFP-15 expression was not linked to pCR. Histological apocrine differentiation was frequent in molecular apocrine carcinomas (60.7%), and was associated with GCDFP-15 within this group (p = 0.039). CONCLUSIONS: GCDFP-15 expression is higher in tumors with favorable prognostic features. GCDFP-15 expression is further a frequent feature of AR positive tumors and the molecular apocrine subtype. It might have reduced sensitivity as a diagnostic marker for mammary differentiation in triple negative tumors as compared to HR or HER2 positive tumor types. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-546) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4122770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41227702014-08-07 Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes Darb-Esfahani, Silvia von Minckwitz, Gunter Denkert, Carsten Ataseven, Beyhan Högel, Bernhard Mehta, Keyur Kaltenecker, Gabriele Rüdiger, Thomas Pfitzner, Berit Kittel, Kornelia Fiedler, Bettina Baumann, Klaus Moll, Roland Dietel, Manfred Eidtmann, Holger Thomssen, Christoph Loibl, Sibylle BMC Cancer Research Article BACKGROUND: Gross cystic disease fluid protein 15 (GCDFP-15), which is regulated by the androgen receptor (AR), is a diagnostic marker for mammary differentiation in histopathology. We determined the expression of GCDFP-15 in breast cancer subtypes, its potential prognostic and predictive value, as well as its relationship to AR expression. METHODS: 602 pre-therapeutic breast cancer core biopsies from the phase III randomized neoadjuvant GeparTrio trial (NCT00544765) were investigated for GCDFP-15 expression by immunohistochemistry. Expression data were correlated with disease-free (DFS) and overall survival (OS) time as well as pathological complete response (pCR) to neoadjuvant chemotherapy. RESULTS: 239 tumors (39.7%) were GCDFP-15 positive. GCDFP-15 expression was positively linked to hormone receptor (HR) and HER2 positive tumor type, while most triple negative carcinomas were negative (p < 0.0001). GCDFP-15 was also strongly correlated to AR expression (p 0.001), and to the so-called molecular apocrine subtype (HR-/AR+, p < 0.0001). Higher rates of GCDFP-15 positivity were seen in tumors of lower grade (<0.0001) and negative nodal status (p = 0.008). GCDFP-15 positive tumors tended to have a more favourable prognosis than GCDFP-15 negative tumors (DFS (p = 0.052) and OS (p = 0.044)), which was not independent from other factors in multivariate analysis. GCDFP-15 expression was not linked to pCR. Histological apocrine differentiation was frequent in molecular apocrine carcinomas (60.7%), and was associated with GCDFP-15 within this group (p = 0.039). CONCLUSIONS: GCDFP-15 expression is higher in tumors with favorable prognostic features. GCDFP-15 expression is further a frequent feature of AR positive tumors and the molecular apocrine subtype. It might have reduced sensitivity as a diagnostic marker for mammary differentiation in triple negative tumors as compared to HR or HER2 positive tumor types. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-546) contains supplementary material, which is available to authorized users. BioMed Central 2014-07-28 /pmc/articles/PMC4122770/ /pubmed/25070172 http://dx.doi.org/10.1186/1471-2407-14-546 Text en © Darb-Esfahani et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Darb-Esfahani, Silvia von Minckwitz, Gunter Denkert, Carsten Ataseven, Beyhan Högel, Bernhard Mehta, Keyur Kaltenecker, Gabriele Rüdiger, Thomas Pfitzner, Berit Kittel, Kornelia Fiedler, Bettina Baumann, Klaus Moll, Roland Dietel, Manfred Eidtmann, Holger Thomssen, Christoph Loibl, Sibylle Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes |
title | Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes |
title_full | Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes |
title_fullStr | Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes |
title_full_unstemmed | Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes |
title_short | Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes |
title_sort | gross cystic disease fluid protein 15 (gcdfp-15) expression in breast cancer subtypes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122770/ https://www.ncbi.nlm.nih.gov/pubmed/25070172 http://dx.doi.org/10.1186/1471-2407-14-546 |
work_keys_str_mv | AT darbesfahanisilvia grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT vonminckwitzgunter grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT denkertcarsten grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT atasevenbeyhan grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT hogelbernhard grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT mehtakeyur grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT kalteneckergabriele grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT rudigerthomas grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT pfitznerberit grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT kittelkornelia grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT fiedlerbettina grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT baumannklaus grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT mollroland grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT dietelmanfred grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT eidtmannholger grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT thomssenchristoph grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes AT loiblsibylle grosscysticdiseasefluidprotein15gcdfp15expressioninbreastcancersubtypes |